NCT05832515View on ClinicalTrials.gov

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2026

Conditions
Multiple Sclerosis
Interventions
DRUG

Fludarabine Phosphate for Injection

Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.

Trial Locations (1)

197022

RECRUITING

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER